INFLUENZA AND OTHER VIRUSES IN THE ACUTELY ILL

Supplementary Materials

Vaccine Effectiveness of Primary Series and Booster Doses against Omicron Variant COVID-19-Associated Hospitalization in the United States

The IVY Network

Corresponding Author: Wesley H. Self, MD, MPH; Vanderbilt University Medical Center; Nashville, Tennessee USA. Email: <u>wesley.self@vumc.org</u>.

Contents

Supplementary Appendix A: Investigators and Collaborators	2
Appendix B: Supplementary Tables	4
Table S1. IVY Network COVID-19 vaccine effectiveness publications.	4
Table S2. Underlying medical conditions	6
Table S3. Classification of vaccination groups.	8
Table S4. Booster dose eligibility.	10
Table S5. Healthy volunteers in antibody evaluation.	11
Table S6. Anti-SARS-CoV-2 antibody concentrations	12
Appendix C: Supplementary Figures	13
Figure S1. Participant flow diagram	13

INFLUENZA AND OTHER VIRUSES IN THE ACUTELY ILL

Supplementary Appendix A: Investigators and Collaborators

Investigators and collaborators in the Influenza and Other Viruses in the Acutely III (IVY) Network

Baylor, Scott and White, Temple, Texas

Manjusha Gaglani, Tresa McNeal, Shekhar Ghamande, Nicole Calhoun, Kempapura Murthy, Judy Herrick, Amanda McKillop, Eric Hoffman, Martha Zayed, Michael Smith

Baystate Medical Center, Springfield, Massachusetts

Jay Steingrub, Lori-Ann Kozikowski, Lesley De Souza, Scott Ouellette

Beth Israel Medical Center, Boston Massachusetts

Nathan I. Shapiro, Michael Bolstad, Brianna Coviello, Robert Ciottone, Arnaldo Devilla, Ana Grafals, Conor Higgins, Carlo Ottanelli, Kimberly Redman, Douglas Scaffidi, Alexander Weingart

Centers for Disease Control and Prevention (CDC), Atlanta, Georgia

Manish Patel, Mark Tenforde, Nathaniel Lewis, Samantha Olson, Meagan Stephenson, Katherine Adams, Diya Surie, Meredith McMorrow, Maraia Tremarelli, Caitlin Turbyfill

Cleveland Clinic, Cleveland, Ohio

Omar Mehkri, Megan Mitchell, Zachary Griffith, Connery Brennan, Kiran Ashok, Bryan Poynter, Abhijit Duggal

Emory University, Atlanta, Georgia Laurence Busse, Caitlin ten Lohuis, Nicholas Stanley, Sophia Zhang

Hennepin County Medical Center, Minneapolis, Minnesota

Matthew Prekker, Heidi Erickson, Anne Frosch, Audrey Hendrickson, Sean Caspers, Walker Tordsen, Olivia Kaus, Tyler Scharber

Intermountain Medical Center, Murray, Utah

Ithan Peltan, Samuel Brown, Jenna Lumpkin, Cassie Smith, Hunter Marshall

Johns Hopkins University, Baltimore, Maryland

David N, Hager, Arber Shehu, Harith Ali, Richard E. Rothman

Montefiore Medical Center, Bronx, New York

Michelle Gong, Amira Mohamed, Rahul Nair, Jen-Ting (Tina) Chen

Ohio State Medical Center, Columbus, Ohio

Matthew Exline, Sarah Karow, Emily Robart, Paulo Nunes Maldonado, Maryiam Khan, Preston So, Madison So, Elizabeth Schwartz, Mena Botros

Oregon Health and Sciences University, Portland, Oregon

Akram Khan, Catherine L. Hough, Haeun Jung, Jesus Martinez, Andrea Luong, Bao Huynh, Habiba Ibrahim, Cynthia Villanueva-Vargas, Juliana Villanueva-Vargas, Suha Quadri

Stanford University, Stanford, California

Jennifer G. Wilson, Alexandra June Gordon, Joe Levitt, Cynthia Perez, Anita Visweswaran, Jonasel Roque

University of California-Los Angeles, Los Angeles, California

Nida Qadir, Steven Chang, Trevor Frankel, Omai Garner, Sukantha Chandrasekaran

University of Colorado, Aurora, Colorado

Adit Ginde, David Douin, Kelly Jensen, David Huynh, Aimee Steinwand, Cori Withers

University of Iowa, Iowa City, Iowa

Nicholas Mohr, Anne Zepeski, Paul Nassar, Shannon Landers, Karin Nielsen, Noble Briggs, Cathy Fairfield

University of Miami, Miami, Florida

Chris Mallow, Hayley Gershengorn, Carolina Rivas

University of Michigan, Ann Arbor, Michigan

Emily Martin, Arnold Monto, Adam Lauring, EJ McSpadden, Rachel Truscon, Anne Kaniclides, Lara Thomas, Ramsay Bielak, Weronika Damek Valvano, Rebecca Fong, William J. Fitzsimmons, Christopher Blair, Julie Gilbert, Leigh Baker

University of Washington, Seattle, Washington

Nicholas Johnson, Vasisht Srinivasan, Christine D. Crider, Kyle A. Steinbock, Thomas C. Paulsen, Layla A. Anderson

Vanderbilt University Medical Center, Nashville, Tennessee

Wesley H. Self, H. Keipp Talbot, Chris Lindsell, Carlos Grijalva, Ian Jones, Natasha Halasa, James Chappell, Kelsey Womack, Jillian Rhoads, Adrienne Baughman, Christy Kampe, Jakea Johnson, Jake Sturgill, Kim Hart, Robert McClellan, Todd Rice, Jonathan Casey, William B. Stubblefield, Yuwei Zhu, Laura L. Short, Lauren J. Ezzell, Margaret E. Whitsett, Rendie E. McHenry, Samarian J. Hargrave, Marcia Blair, Jennifer L. Luther, Claudia Guevara Pulido, Bryan P. M. Peterson

Wake Forest University, Winston-Salem, North Carolina

D. Clark Files, Kevin Gibbs, Mary LaRose, Leigha Landreth, Madeline Hicks, Lisa Parks

Washington University, St. Louis, Missouri

Hilary Babcock, Jennie Kwon, Jahnavi Bongu, David McDonald, Candice Cass, Sondra Seiler, David Park, Tiffany Hink, Meghan Wallace, Carey-Ann Burnham, Olivia G. Arter

Table S1. IVY Network COVID-19 vaccine effectiveness publications.

The IVY Network publishes vaccine effectiveness (VE) estimates iteratively, with later publications adding sample size and focusing on specific questions that were not addressed in earlier publications. Some participants are included in multiple publications. The current manuscript includes participants enrolled during December 26, 2021–April 30, 2022 and focuses on vaccine effectiveness against the Omicron variant.

Publication	Primary Question Addressed	Data cut (cohort initiated March 11, 2021)	Sample size	Primary finding
Clin Infect Dis 2021. PMID: 34358310.	COVID-19 mRNA VE against hospitalization during the early phase of the US COVID-19 program.	May 5, 2021	1,212	mRNA VE against COVID-19 hospitalization among US adults = 87.1% (95% CI: 81–91)
MMWR 2021. PMID: 34437524	COVID-19 mRNA VE against hospitalization beyond 12 weeks from full vaccination.	July 14, 2021	3,089	mRNA VE against COVID-19 hospitalization from 13–24 weeks post-vaccination among US adults = 84% (95% CI: 77–90)
MMWR 2021. PMID: 34555004	Comparative effectiveness of COVID-19 vaccines available in the United States for preventing COVID-19 hospitalizations among immunocompetent adults	August 15, 2021	3,689	VE against COVID-19 hospitalizations varied by vaccine product among immunocompetent adults – Moderna: 93% (95% CI: 91–95); Pfizer BioNTech: 88% (95% CI: 85–91); Janssen: 71% (95% CI: 56–81).
JAMA 2021. PMID: 34734975	Effectiveness of mRNA vaccines to prevent disease progression to critical illness or death among adults hospitalized with COVID-19.	August 15, 2021	4,513	Prior vaccination was associated with a 67% (95% CI: 42–81) relative risk reduction lower risk of progression to invasive mechanical ventilation or death among adults hospitalized with COVID-19, suggesting vaccination attenuated disease severity.
MMWR 2022. PMID: 35085218	Effectiveness of a Third Dose of Pfizer-BioNTech and Moderna Vaccines in Preventing COVID-19 Hospitalization Among Immunocompetent and Immunocompromised Adults - United States, August-December 2021	August 19– December 15, 2021	2,952	Three doses of mRNA COVID-19 vaccine provide greater protection against COVID-19 hospitalization than two doses. For immunocompetent adults, VE against hospitalization was 97% for three doses and 82% for two doses. For immunocompromised adults, VE against hospitalization was 88% for three doses and 69% for two doses.

Publication	Primary Question Addressed	Data cut (cohort initiated March 11, 2021)	Sample size	Primary finding
BMJ 2022; PMID: 35264324	Clinical Severity of, and effectiveness of mRNA vaccines against, COVID- 19 from Omicron, Delta, and Alpha SARS-CoV-2 Variants in the United States	January 14, 2022	11,690	VE against COVID-19 hospitalization during the period that Delta variant dominated was 85% (95% CI: 83–87) for 2 mRNA vaccine doses and 94% (95% CI: 92–95) for 3 vaccine doses; for the early period that Omicron variant dominated VE was 65% (95% CI: 51–75) for 2 doses and 86% (95% CI: 77–91) for 3 doses. In-hospital COVID- 19 severity was lower for Omicron than Delta. Prior vaccination was associated with lower in-hospital COVID-19 severity for Alpha, Delta, and Omicron variants.
MMWR 2022; PMID: 35324878	mRNA vaccine effectiveness during the alpha and delta periods against invasive mechanical ventilation and death	January 24, 2022	7,544	mRNA vaccine effectiveness to prevent death or invasive mechanical ventilation was 90% (95% CI = 88–91).
J Infect Dis 2022; PMID:35385875	mRNA vaccine effectiveness against COVID-19 hospitalization among solid organ transplant recipients.	December 15, 2021	10,420	VE against COVID-19 hospitalizations varied by host immune status with SOT recipients having lower VE for two vaccine doses (29%; 95% CI: -19–58) and three vaccine doses (77%, 95% CI: 48–90) than immunocompetent people.

Table S2. Underlying medical conditions.

Conditions considered	l in this ana	lysis to he	immunocom	nromising are	noted (*)
conditions considered	i ini tins ana	19313 10 00	mmunocom	promising are	noteu ().

Conditions considered in this analysis to be immunocompromising are noted (*).
Cardiovascular disease
Heart failure
Peripheral vascular disease that limits mobility
Prior myocardial infarction
Cardiac arrhythmias including atrial fibrillation and ventricular arrhythmias
Valvular heart disease
Hypertension
Neurologic disease
Dementia
Prior stroke
Prior transient ischemic attack (TIA, "mini-stroke")
Brain or spinal cord injury with loss of limb function
Cerebral palsy
Muscular dystrophy
Multiple sclerosis
Myasthenia gravis
Anterolateral sclerosis (ALS)
Pulmonary disease
Asthma
Chronic obstructive pulmonary disease
Cystic fibrosis
Pulmonary fibrosis
Pulmonary hypertension
Home oxygen use (except at night for sleep disorder)
Tracheostomy
Home non-invasive ventilation use (except at night for sleep disorder)
Home invasive ventilation use
Gastrointestinal disease
Feeding through a tube
Inflammatory bowel disease including Crohn's Disease or Ulcerative Colitis*
Cirrhosis (clinical diagnosis of cirrhosis)
Chronic liver disease without cirrhosis
Peptic ulcer disease
Endocrine disease
Diabetes mellitus without end organ damage
Diabetes mellitus with end organ damage
Adrenal insufficiency
Hypothyroidism
Renal disease
Chronic kidney disease without chronic renal replacement therapy
End stage renal disease on chronic renal replacement therapy (including hemodialysis or peritoneal
dialysis)
Prior kidney transplant*

Hematologic disease
Sickle cell disease (all variants)
Prior stem cell or bone marrow transplant*
Coagulopathy or other bleeding disorder, such as hemophilia
Chronic anemia
Thalassemia
Cancer/Malignancy
Active solid organ cancer without metastases; active cancer defined as treatment for the cancer or
newly diagnosed cancer in the past 6 months*
Active solid organ cancer with metastases; active cancer defined as treatment for the cancer or
newly diagnosed cancer in the past 6 months*
Active hematologic cancer (such as leukemia/lymphoma/myeloma) or active cancer defined as
treatment for the cancer or newly diagnosed cancer in the past 6 months*
Other immunosuppression
Human Immunodeficiency Virus (HIV) infection without AIDS*
AIDS*
Congenital immunodeficiency disorder*
Prior splenectomy*
Prior solid organ transplant*
Immunosuppression medication*
Other immunosuppression condition
Autoimmune
Systemic Lupus Erythematosus*
Rheumatoid arthritis*
Psoriasis*
Scleroderma*
Other autoimmune disease
Other
Unintentional weight loss of at least 10 pounds in past 90 days
Sarcoidosis
Amyloidosis

Table S3. Classification of vaccination groups.

Definitions of vaccination groups included in this analysis -21 hospitals in 18 US states, December 26, 2021-April 30, 2022

Vaccination group	Immunosuppression	Doses	Product						Interval	Patients
	status ^a	received	First	Second	Third	Fourth	Fifth	Sixth	between	included in this
			dose	dose	dose	dose	dose	dose	last dose	analysis (Total
									and	N=3,181)
									illness	
									onset	
Unvaccinated		0								1,057/3,181
Partially vaccinated		1	Any						0-13 days	(33%) Excluded
	Immunocompotent	1	mRNA ^b						N/A	Excluded
Partially vaccinated	Immunocompetent	2	mRNA	 mRNA						Excluded
Partially vaccinated	Immunocompetent		1	IIIRINA					0-13 days	
Partially vaccinated	Immunocompromised	1	mRNA						N/A	Excluded
Partially vaccinated	Immunocompromised	2	mRNA	mRNA					N/A	Excluded
Partially vaccinated	Immunocompromised	3	mRNA	mRNA	mRNA				0-6 days	Excluded
Partially vaccinated	Immunocompromised	1	l&l₀						N/A	Excluded
Partially vaccinated	Immunocompromised	2	1&1	Any					0-6 days	Excluded
Completed primary series	Immunocompetent	1	1&1						≥14 days	98/3,181 (3%)
Completed primary series	Immunocompetent	2	1&1	Any					0-6 days	12/3,181 (0%)
Completed primary series	Immunocompetent	2	mRNA	mRNA					≥14 days	711/3,181 (22%)
Completed primary series	Immunocompetent	3	mRNA	mRNA	Any				0-6 days	40/3,181 (1%)
Completed primary series	Immunocompromised	2	1&1	Any					≥7 days	0/3,181 (0%)
Completed primary series	Immunocompromised	3	1&1	Any	Any				0-6 days	0/3,181 (0%)
Completed primary series	Immunocompromised	3	mRNA	mRNA	mRNA				≥7 days	465/3,181 (15%)
Completed primary series	Immunocompromised	4	mRNA	mRNA	mRNA	Any			0-6 days	0/3,181 (0%)
Primary series + booster dose	Immunocompetent	2	1&1	Any					≥7 days	80/3,181 (3%)
Primary series + booster dose	Immunocompetent	3	1&1	Any	Any				0-6 days	0/3,181 (0%)
Primary series + booster dose	Immunocompetent	3	mRNA	mRNA	Any				≥7 days	710/3,181 (22%)
Primary series + booster dose	Immunocompetent	4	mRNA	mRNA	Any	Any			0-6 days	3/3,181 (0%)
Primary series + booster dose	Immunocompromised	3	1&1	Any	Any				≥7 days	1/3,181 (0%)
Primary series + booster dose	Immunocompromised	4	1&1	Any	Any	Any			0-6 days	0/3,181 (0%)
Primary series + booster dose	Immunocompromised	4	mRNA	mRNA	mRNA	Any			≥7 days	4/3,181 (0%)
Primary series + booster dose	Immunocompromised	5	mRNA	mRNA	mRNA	Any	Any		0-6 days	0/3,181 (0%)

^a Immunocompromising conditions included: active solid organ cancer (active cancer defined as treatment for the cancer or newly diagnosed cancer in the past 6 months), active hematologic cancer (such as leukemia, lymphoma, or myeloma), HIV infection without AIDS, AIDS, congenital immunodeficiency syndrome, previous splenectomy, previous solid organ transplant, immunosuppressive medication, systemic lupus erythematosus, rheumatoid arthritis, psoriasis, scleroderma, or inflammatory bowel disease, including Crohn's disease or ulcerative colitis.

^b mRNA vaccine refers to either BNT162b2 (Pfizer-BioNTech) or mRNA-1273 (Moderna)

^c J&J refers to Ad26.COV2 (Johnson & Johnson [Janssen])

Table S4. Booster dose eligibility.

Date	Authorization
August 13, 2021	Immunocompromised patients recommended to receive an additional primary
	series dose of Pfizer-BioNTech or Moderna vaccine, following initial series of 2
	doses of mRNA
	Contare for Disease Control and Drovention, ACID Presentation Slides: August 12, 2021 Meeting
	[Centers for Disease Control and Prevention. ACIP Presentation Slides: August 13, 2021 Meeting. Updated August 13, 2021. Accessed April 15, 2022
	https://www.cdc.gov/vaccines/acip/meetings/slides-2021-08-13.html)]
September 22, 2021	Individuals ≥65 years, those at high risk of COVID-19-associated hospitalization,
	and immunocompromised patients recommended to receive a booster dose of
	Pfizer-BioNTech, following primary series of mRNA or Janssen (Johnson &
	Johnson)
	[Centers for Disease Control and Prevention. ACIP Presentation Slides: Sept 22-23, 2021
	Meeting. Updated September 23, 2021. Accessed April 15, 2022,
	https://www.cdc.gov/vaccines/acip/meetings/slides-2021-09-22-23.html]
October 21, 2021	Moderna and Janssen (Johnson & Johnson) recommended for use as booster
	dose products for immunocompromised, ≥65 years, and high-risk individuals
	[Mbaeyi S, Oliver SE, Collins JP, et al. The Advisory Committee on Immunization Practices'
	Interim Recommendations for Additional Primary and Booster Doses of COVID-19 Vaccines -
	United States, 2021. MMWR Morb Mortal Wkly Rep. Nov 05 2021;70(44):1545-1552.
	doi:10.15585/mmwr.mm7044e2]
November 19, 2021	All adults (≥18 years) recommended to receive a booster dose of Pfizer-
	BioNTech or Moderna vaccine, following primary series of 2 doses of mRNA or
	1 dose of Janssen (Johnson & Johnson)
	[Centers for Disease Control and Prevention. ACIP Presentation Slides: November 19, 2021
	Meeting. Updated November 19, 2021. Accessed April 15, 2022,
	https://www.cdc.gov/vaccines/acip/meetings/slides-2021-11-19.html
March 29, 2022	Individuals ≥50 years or immunocompromised allowed to receive a second
	booster dose of Pfizer-BioNTech or Moderna vaccine, following primary series
	and first booster dose
	[Centers for Disease Control and Prevention. CDC Recommends Additional Boosters for Certain
	Individuals. Updated March 29, 2022. Accessed April 15, 2022,
	https://www.cdc.gov/media/releases/2022/s0328-covid-19-boosters.html
May 19, 2022	Individuals ≥50 years or immunocompromised recommended to receive a
	second booster dose of Pfizer-BioNTech or Moderna vaccine, following primary
	series and first booster dose
	[Centers for Disease Control and Prevention. CDC Strengthens Recommendations and Expands
	Eligibility for COVID-19 Booster Shots. Updated May 19, 2022. Accessed May 20, 2022,
	https://www.cdc.gov/media/releases/2022/s0519-covid-booster-acip.html

Timeline of eligibility for additional and booster doses of COVID-19 vaccines

Table S5. Healthy volunteers in antibody evaluation.

Characteristics of healthy volunteers in the analysis of anti-SARS-CoV-2 antibody concentrations after COVID-19 booster doses.

Characteristic	BNT162b2 three dose series (n=33)	mRNA-1273 three dose series (n=16)	Ad26.COV2 two dose series (n=8)	Ad26.COV2 one dose, then mRNA booster (n=6)
Age, median (IQR), years	48 (32 <i>,</i> 57.75)	43 (26.5, 67.5)	55 (51 <i>,</i> 56.75)	57.5 (36.75, 63.25)
Female sex, no. (%)	21(63.6)	8 (50)	3 (37.5)	4 (66.7)
Male sex, no. (%)	12 (36.4)	8 (50)	5 (62.5)	2 (33.3)
Race/ethnicity, no. (%)				
Non-Hispanic White	25 (75.8)	14 (87.5)	8 (100)	5 (83.3)
Non-Hispanic Black	6 (18.2)	2 (12.5)	0 (0)	0 (0)
Hispanic	2 (6.1)	0 (0)	0 (0)	0 (0)
Non-Hispanic Asian	0 (0)	0 (0)	0 (0)	0 (0)
Non-Hispanic American Indian or Alaska Native	0 (0)	0 (0)	0 (0)	1 (16.7)
Non-Hispanic Native Hawaiian or Other Pacific Islander	0 (0)	0 (0)	0 (0)	0 (0)
Non-Hispanic, all other races	0 (0)	0 (0)	0 (0)	0 (0)
Time between full vaccination and receipt of booster, median (IQR), days	240 (219.5, 284)	233 (208, 255.5)	233 (219, 244.75)	230.5 (219.25, 238)
Time between receipt of booster and post-booster blood draw, median (IQR), days	23 (18, 29.5)	19 (16.5, 30)	25 (22.5, 29.5)	25.5 (18, 32.25)

Table S6. Anti-SARS-CoV-2 antibody concentrations.

Anti-SARS-CoV-2 antibody concentrations among healthy volunteers after full COVID-19 vaccination, before a first booster dose, and after a first booster dose. Results for individual patients are shown in Figure 4.

COVID-19 vaccine		Anti-RBD concentrat geometric mean (955	• • •	Anti-spike concentration (BAU/ml), geometric mean (95% Cl)		
series	n	Before booster	2-6 weeks after	Before booster	2-6 weeks after	
		dose	booster dose	dose	booster dose	
BNT162b2 three	33	199.3 (142.3,279.3)	8708.7 (6547.6,	156.7 (116.5,	5897.9 (4446.4,	
dose series			11583.2)	210.8)	7823.3)	
mRNA-1273 three	16	467.0 (293.8,	10479.0 (7765.2,	340.3 (216.1,	6986.2 (5058.2 <i>,</i>	
dose series		742.3)	14141.4)	536.1)	9649.2)	
Ad26.COV2 two	8	51.1 (27.1, 96.5)	961.2 (431.7,	37.1 (20.9, 66.1)	702.2 (318.2,	
dose series			2140.1)		1549.8)	
Ad26.COV2 one	6	38.6 (7.0, 213.1)	3781.1 (1517.3,	29.9 (5.82, 154.2)	2669.9 (1093.3,	
dose, then mRNA			9422.3)		6519.9)	
booster						

(A) All participants with antibody measurements before and after booster dose.

Abbreviations: BAU = binding antibody units

(B) Subset of participants with antibody measurements before and after a booster dose who also had antibody measurements after full vaccination.

COVID-19		Anti-RBD concentration (BAU/ml), geometric mean (95% Cl)			Anti-spike concentration (BAU/ml), geometric mean (95% Cl)		
vaccine series	n		Before	2-6 weeks	2-6 weeks	Before	2-6 weeks
vaccine series		2-6 weeks after	booster	after booster	after full	booster	after booster
		full vaccination	dose	dose	vaccination	dose	dose
BNT162b2	9	3078.7 (1554.6,	246.9	10484.9	2989.7	205.9	7260.2
three dose		6097.0)	(116.6,	(6380.4,	(1568.8,	(126.0,	(3842.43,
series			523.2)	17229.8)	5697.6	336.3)	13717.9)
mRNA-1273	7	4912.7 (3283.3,	895.9	12856.2	3487.8	573.7	8257.1
three dose		7350.8)	(558.3 <i>,</i>	(7205.7,	(2199.7,	(343.5,	(4558.2,
series			1437.6)	22937.9)	5530.2)	958.3)	14957.6)
Ad26.COV2 two	3	12.76 (4.7,	26.3	501.2 (35.3,	11.79 (3.31,	22.2 (4.9,	360.4 (27.9,
dose series		34.5)	(12.5,	7110.4)	41.9)	100.8)	4655.3)
			55.7)				
Ad26.COV2 one	2	77.6 (66.2,	20.62 (0,	2361.2 (0.1,	116.6 (3.09,	18.6 (0,	1646.8 (0.1,
dose, then		91.0)	453557.5)	1049821470	4389.5)	583040.7)	46373002)
mRNA booster							

Abbreviations: BAU = binding antibody units

Appendix C: Supplementary Figures

Figure S1. Participant flow diagram.

